Clinical pharmacology and pharmacogenetics of gemcitabine

Abstract

Gemcitabine is a cytotoxic nucleoside analog, which is widely used in the treatment of malignancies. Interindividual differences in gemcitabine pharmacokinetics and pharmacodynamics have been demonstrated. Pharmacogenetic factors may account for a significant proportion of these differences. This review provides an update on the pharmacogenetics of gemcitabine and its influence on gemcitabine efficacy and toxicity.

Keywords::

• Gemcitabine
• pharmacogenetics
• pharmacokinetics

Acknowledgments

This work was supported by funding to RAS from the National Healthcare Group (NHG-RISE 0703).

Declaration of interest: The authors report no financial conflicts of interest. The authors alone are responsible for the content and writing of this paper.